J.S. Ahn

机构：Samsung Medical Center, Sungkyunkwan University

发表论文 6 篇 · 总被引 31 次 · h-index 3

代表论文

Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study (2025 · Annals of Oncology · 被引 20)
1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo) (2024 · Annals of Oncology · 被引 6)
57O Randomized double-blind phase II trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC: Primary results (2022 · Immuno-Oncology Technology · 被引 3)
44P Dostarlimab (Dos) or pembrolizumab (Pem) + chemotherapy (CT) in previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC): Patient (Pt) and disease characteristics subgroup analyses from the PERLA trial (2023 · Journal of Thoracic Oncology · 被引 2)
17P: Final analysis of PERLA, a global, randomized, phase II double-blind trial of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy in metastatic nonsquamous non-small cell lung cancer (2025 · Journal of Thoracic Oncology)
EP11.02-07 Dostarlimab + CT vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC: Asian Subgroup Analyses of the PERLA Trial (2023 · Journal of Thoracic Oncology)